MicroPort®`s Firehawk® Drug Eluting Stent Achieves Primary End...
(WorldNews China)

Paris, France - On May 23, 2018, Shanghai MicroPort Medical (Group) Co., Ltd. (`MicroPort®`) announced primary endpoint data at 12 months and QCA angiography data at 13 months from its TARGET All-Comers (`TARGET AC`) trial. The results of the TARGET AC trial demonstrated that vessels treated with the Firehawk® Rapamycin Target Eluting Coronary Stent System (`Firehawk®`) showed non-inferiority results when compared to vessels treated with the Xience family of drug eluting stents. These TARGET AC clinical data were presented for the first time during a late-breaking clinical trials session at the Euro-PCR conference held in Paris by Dr. Andreas Baumbach, a co-principal investigator of TARGET...